Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01656460 · ClinicalTrials.gov registry record · NA
Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer
A NA study of Lung Cancer, sponsored by Dr Thomas DiPetrillo.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 2
- Study locations
NCT01656460: Completed NA study of Lung Cancer, sponsored by Dr Thomas DiPetrillo.
NCT01656460 is a NA study of Lung Cancer that has completed, run by Dr Thomas DiPetrillo. The registered enrollment target is 12 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01656460, a NA study of Lung Cancer, has completed, sponsored by Dr Thomas DiPetrillo.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and toxicity stereotactic body radiation (SBRT) as consolidation following standard chemoradiation for patients with stage III non-small cell lung cancer.
Conditions Studied
Interventions
- RADIATION Stereotactic radiation Arm 1
- RADIATION Stereotactic radiation Arm 2
- RADIATION Stereotactic radiation Arm 3
- RADIATION Stereotactic radiation Arm 4
Study Locations (2)
Rhode Island
- memorial Hospital of Rhode island - Pawtucket
- Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2012-04 |
| Est. Completion | 2017-05-16 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01656460
The ClinicalTrials.gov registry entry for NCT01656460 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Dr Thomas DiPetrillo, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 4 interventions - of which Stereotactic radiation Arm 1 is the first listed.
NCT01656460 reports 2 study locations spanning 1 distinct geographic area - top geographies include Rhode Island.
Frequently Asked Questions
What is clinical trial NCT01656460 about?
NCT01656460 is a clinical study titled "Stereotactic Body Radiation for Consolidation After Standard Chemoradiation for Stage 3 Lung Cancer". The purpose of this study is to evaluate the efficacy and toxicity stereotactic body radiation (SBRT) as consolidation following standard chemoradiation for patients with stage III non-small cell lung cancer.
What is the current status of trial NCT01656460?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2012-04. Estimated completion is 2017-05-16.
What conditions does trial NCT01656460 study?
This clinical trial studies the following conditions: Lung Cancer.
What interventions are being tested in trial NCT01656460?
The interventions under investigation include: Stereotactic radiation Arm 1 (RADIATION), Stereotactic radiation Arm 2 (RADIATION), Stereotactic radiation Arm 3 (RADIATION), Stereotactic radiation Arm 4 (RADIATION).
Who is sponsoring clinical trial NCT01656460?
This trial is sponsored by Dr Thomas DiPetrillo, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01656460 being conducted?
This trial has 2 study locations across Rhode Island. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
RECRUITING · NA
-
Lung Cancer Screening in High-risk Black Individuals
RECRUITING · NA
-
A Patient and Provider Intervention to Address Health Disparities in Lung Cancer Screening
RECRUITING · NA
-
Exercise as Maintenance Therapy in Advanced Lung Cancer
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Stereotactic Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.